MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED (Ireland)
Inventor
Potenziano, James
Abstract
A gas delivery system is provided. The gas delivery system includes a pump operable to receive blood from a patient. A gas transfer unit is in fluid communication with the pump and operable to receive the blood from the pump and deliver a therapeutic amount of xenon gas to the blood. A patient connector withdraws and/or infuses the blood into the patient.
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED (Ireland)
Inventor
Clark, Peter James
Assambo, Cedric
Mcatamney, Michael
Klaus, John
Roehl, Robin
Abstract
A removable gas sensor module is provided for a therapeutic gas delivery device. The gas sensor module includes a sample chamber which receives a sample gas from the therapeutic gas delivery device. A gas detection unit includes a plurality of sensors operable to measure at least one property of the sample gas. The sensors include two or more of a gas detection sensor, a humidity sensor, a temperature sensor, or a combination thereof. The gas sensor module is self-contained within the therapeutic gas delivery device and swappable with another gas sensor module.
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Goldstein, Brahm
Greene, Douglas Stuart
Abstract
Described are methods of administering therapeutic gases comprising high concentrations of nitric oxide, particularly concentrations above 2,000 ppm. The therapeutic gas may be administered at a certain dosing rate, such as less than 166 micrograms of nitric oxide per second. Also described are methods of administering a therapeutic gas comprising nitric oxide to a patient, wherein a dose of nitric oxide is administered from a portable device that includes a delivery system and a mini-cylinder. Methods of intermittent administration of nitric oxide pulses are also described.
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Flanagan, Craig
Freed, Simon
Klaus, John
Kohlmann, Thomas
Meglasson, Martin D.
Naidu, Manesh
Shah, Parag
Abstract
The present invention generally relates to, amongst other things, systems, devices, materials, and methods that can improve the accuracy and/or precision of nitric oxide therapy by, for example, reducing the dilution of inhaled nitric oxide (NO). As described herein, NO dilution can occur because of various factors. To reduce the dilution of an intended NO dose, various exemplary nasal cannulas, pneumatic configurations, methods of manufacturing, and methods of use, etc. are disclosed.
A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
6.
Systems and methods for intelligent gas source management and/or systems and methods for delivery of therapeutic gas and/or enhanced performance verification for therapeutic gas delivery
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Acker, Jaron M.
Tolmie, Craig R.
Roehl, Robin
Schmidt, Jeffrey
Milsap, Jeff
Abstract
Therapy gas delivery systems that provide run-time-to-empty information to a user of the system and methods for administering therapeutic gas to a patient. The therapeutic gas delivery system may include a gas pressure sensor attachable to a therapeutic gas source that communicates therapeutic gas pressure data to a therapeutic gas delivery system controller, a gas temperature sensor positioned to measure gas temperature in the therapeutic gas source that communicates therapeutic gas temperature data to the therapeutic gas delivery system controller, at least one flow controller that communicates therapeutic gas flow rate data to the therapeutic gas delivery system controller, at least one flow sensor that communicates flow rate data to the therapeutic gas delivery system controller, and at least one display that communicates run-time-to-empty to a user of the therapeutic gas delivery system. The therapeutic gas delivery system controller of the system includes a processor that executes an algorithm to calculate the run-time-to-empty from the data received from the gas pressure sensor, temperature sensor, flow controller and flow sensor, and directs the result to the display.
G01F 22/02 - Methods or apparatus for measuring volume of fluids or fluent solid material, not otherwise provided for involving measurement of pressure
A61M 16/20 - Valves specially adapted to medical respiratory devices
A61M 16/12 - Preparation of respiratory gases or vapours by mixing different gases
A61M 16/10 - Preparation of respiratory gases or vapours
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Montgomery, Frederick J.
Bathe, Duncan P.
Abstract
th breath, where n is greater than or equal to 1. The pharmaceutical gases include CO and NO, both of which are provided as a concentration in a carrier gas. The gas control system determines the delivery of the pharmaceutical gas to the patient to result in the known desired quantity (e.g. in molecules, milligrams or other quantified units) of the pharmaceutical gas being delivered. Upon completion of that known desired quantity of pharmaceutical gas over a plurality of breaths, the system can either terminate, continue, activate and alarm, etc.
A61M 16/10 - Preparation of respiratory gases or vapours
9.
Systems and method for delivery of therapeutic gas to patients, in need thereof, receiving breathing gas from a ventilator that varies at least pressure and/or flow using enhanced therapeutic gas (NO) flow measurement
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Acker, Jaron M.
Tolmie, Craig R.
Abstract
The present disclosure generally relates to systems and methods for delivery of therapeutic gas to patients, in need thereof, receiving breathing gas from a high frequency ventilator using at least enhanced therapeutic gas (e.g., nitric oxide, NO, etc.) flow measurement. At least some of these enhanced therapeutic gas flow measurements can be used to address some surprising phenomenon that may, at times, occur when wild stream blending therapeutic gas into breathing gas a patient receives from a breathing circuit affiliated with a high frequency ventilator. Utilizing at least some of these enhanced therapeutic gas flow measurements the dose of therapeutic gas wild stream blended into breathing gas that the patient receives can at least be more accurate and/or under delivery of therapeutic gas into the breathing gas can be avoided and/or reduced.
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Royal, Mike Allan
Breitmeyer, James Bradley
Abstract
Described herein are compositions and methods for intravenous administration of acetaminophen at a single dose level of less than about 1000 mg for the treatment or prevention of pain (e.g., postoperative pain) and/or fever.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
11.
Devices and methods for engaging indexed valve and pressurized canister assembly with collar and for linear actuation by plunger assembly into fluid communication with device for regulating drug delivery
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Montgomery, Frederick J.
Bathe, Duncan P.
Lee, Daniel J.
Biba, Scott I.
Bakken, Todd J.
Abstract
A valve assembly having a housing and a valve, the valve being disposed within the housing, a first indexed member integral to the housing, the first indexed member adapted to be complementary to a second indexed member, and a radio frequency identification device adapted to communicate with a radio frequency receiver, the valve being configured to align with a canister, seal the canister and open in a single movement. A drug containment device having said valve assembly is also disclosed.
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
C07F 7/00 - Compounds containing elements of Groups 4 or 14 of the Periodic Table
A61K 9/00 - Medicinal preparations characterised by special physical form
13.
Cannula for minimizing dilution of dosing during nitric oxide delivery
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Flanagan, Craig
Freed, Simon
Klaus, John
Kohlmann, Thomas
Meglasson, Martin D.
Naidu, Manesh
Shah, Parag
Abstract
Described are nasal cannulas that improve the precision of the delivered dose for nitric oxide therapy by reducing the dilution of nitric oxide. The nasal cannulas may reduce the total volume and potential for retrograde flow during nitric oxide therapy through the design of the specific dimensions of the flow path and/or having check valves in the nitric oxide delivery line and/or having a flapper or umbrella valve dedicated to nitric oxide delivery. The nasal cannulas may also use materials that limit oxygen diffusion through the cannula walls. The nosepiece for these cannulas may be manufactured by a molding technique.
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Schnitman, Robert
Medicis, Joseph J.
Potenziano, Jim
Acker, Jaron
Schmidt, Jeffrey
Abstract
Described is an apparatus for monitoring nitric oxide delivery, wherein such apparatus comprises an indicator to inform a user of the apparatus when the flow of breathing gas rises above or falls below a predetermined level or range. Also described is a method of monitoring nitric oxide delivery, wherein the flow of breathing gas is measured and displayed. In some embodiments, an alert is provided when the flow of breathing gas rises above or falls below a predetermined level or range.
Apparatus and method for humidity conditioning sample gas of a patient breathing circuit affiliated with a ventilator and/or nitric oxide delivery system
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Stanton, John P.
Berndt, John V.
Abstract
A therapeutic gas is administered to a patient. A sample gas is drawn from the therapeutic gas supply, and passed through a water-permeable tubular membrane. Concurrently, a section of the water permeable tubular membrane is maintained as a ventilated water permeable tubular membrane, by exposing outer surfaces of the ventilated water permeable tubular membrane to an ambient air flow. The ambient air flow may in some examples be moved over the tubular membrane via forced air such as for example via a fan associated with a housing surrounding the tubular membrane.
A61B 5/097 - Devices for facilitating collection of breath or for directing breath into or through measuring devices
A61M 16/14 - Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
A61M 16/20 - Valves specially adapted to medical respiratory devices
16.
APPARATUS AND METHOD FOR HUMIDITY CONDITIONING SAMPLE GAS OF A PATIENT BREATHING CIRCUIT AFFILIATED WITH A VENTILATOR AND/OR NITRIC OXIDE DELIVERY SYSTEM
MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED (Ireland)
Inventor
Stanton, John, P.
Berndt, John, V.
Abstract
A therapeutic gas is administered to a patient. A sample gas is drawn from the therapeutic gas supply, and passed through a water-permeable tubular membrane. Concurrently, a section of the water permeable tubular membrane is maintained as a ventilated water permeable tubular membrane, by exposing outer surfaces of the ventilated water permeable tubular membrane to an ambient air flow. The ambient air flow may in some examples be moved over the tubular membrane via forced air such as for example via a fan associated with a housing surrounding the tubular membrane.
MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED (Ireland)
Inventor
Biba, Scott, I.
Abstract
A trap bowl is provided to accumulate liquid droplets from a filter, as a liquid content. The trap bowl includes a transparent vertical prism. The transparent vertical prism includes a face that forms a vertical transparent surface facing against a content of the section. The face can provide a first angle of total reflection when content of the section is a type of gas, and a second angle of total reflection when the content of the section is the liquid content. A light source may emit a light beam incident on the face at an angle of incidence. The angle of incidence results in reflection of the light beam, striking the light receiver, when the face has the first angle of total reflection, and results in refraction of the light beam, missing the light receiver, when the face has the second angle of total reflection.
Apparatus and method for filtering liquid particles from inspiratory gas flow of a patient breathing circuit affiliated with a ventilator and/or nitric oxide delivery system
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Biba, Scott I.
Falligant, John
Abstract
The present disclosure relates to a filter apparatus for filtering liquid from a gas, the apparatus having a first housing having a gas inlet and a gas outlet; a first filter media disposed in the first housing; a second filter media disposed in the housing; and a second housing forming a first collection basin disposed in the flow path between the first filter media and the second filter media, so that a path is defined for the gas flowing from the inlet, through the first filter media, past the collection basin, through the second filter media, and to the outlet. The present disclosure also relates to a method of passing a gas through a coalescing filter media and through a hydrophobic filter media.
B01D 53/22 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by diffusion
A61M 16/10 - Preparation of respiratory gases or vapours
B01D 46/00 - Filters or filtering processes specially modified for separating dispersed particles from gases or vapours
B01D 46/10 - Particle separators, e.g. dust precipitators, using filter plates, sheets or pads having plane surfaces
B01D 46/42 - Auxiliary equipment or operation thereof
19.
APPARATUS AND METHOD FOR FILTERING LIQUID PARTICLES FROM INSPIRATORY GAS FLOW OF A PATIENT BREATHING CIRCUIT AFFILIATED WITH A VENTILATOR AND/OR NITRIC OXIDE DELIVERY SYSTEM
MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED (Ireland)
Inventor
Biba, Scott, I.
Falligant, John
Abstract
The present disclosure relates to a filter apparatus for filtering liquid from a gas, the apparatus having a first housing having a gas inlet and a gas outlet; a first filter media disposed in the first housing; a second filter media disposed in the housing; and a second housing forming a first collection basin disposed in the flow path between the first filter media and the second filter media, so that a path is defined for the gas flowing from the inlet, through the first filter media, past the collection basin, through the second filter media, and to the outlet. The present disclosure also relates to a method of passing a gas through a coalescing filter media and through a hydrophobic filter media.
MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED (Ireland)
Inventor
Potenziano, Jim
Greene, Douglas, Alan
Flanagan, Craig
Abstract
Described are systems and methods for administration of nitric oxide (NO) with use of left ventricular assists devices (LVADs), as well as systems and methods for monitoring the NO delivery devices and/or the LVAD.
MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED (Ireland)
Inventor
Acker, Jaron, M.
Tolmie, Craig, R.
Abstract
The present disclosure generally relates to systems and methods for delivery of therapeutic gas to patients, using techniques to compensate for disruptions in breathing gas flow measurement, such as when breathing gas flow measurement is unavailable or unreliable. Such techniques include using historical breathing gas flow rate data, such as moving average flow rates, moving median flow rates and/or flow waveforms. At least some of these techniques can be used to ensure that interruption in therapeutic gas delivery is minimized or eliminated.
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Acker, Jaron M.
Tolmie, Craig R.
Abstract
The present disclosure generally relates to systems and methods for delivery of therapeutic gas to patients, using techniques to compensate for disruptions in breathing gas flow measurement, such as when breathing gas flow measurement is unavailable or unreliable. Such techniques include using historical breathing gas flow rate data, such as moving average flow rates, moving median flow rates and/or flow waveforms. At least some of these techniques can be used to ensure that interruption in therapeutic gas delivery is minimized or eliminated.
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Acker, Jaron M.
Kohlmann, Thomas
Tolmie, Craig R.
Abstract
Described are methods and devices for therapeutic or medical gas delivery that utilize at least one proportional control valve and at least one binary control valve. The proportional control valve may be in series with the binary control valve to provide a valve combination capable of pulsing therapeutic gas at different flow rates, depending on the setting of the proportional control valve. Alternatively, the proportional control valve and binary control valve may be in parallel flow paths.
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Greene, Douglas Stuart
Medicis, Joseph J.
Potenziano, Jim
Abstract
Methods for identifying premature infants at risk for developing bronchopulmonary dysplasia and/or most likely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia (BPD). Methods for treating premature infants identified as at risk and/or likely to benefit are provided. also provided are methods for identifying premature infants that are not at risk for developing bronchopulmonary dysplasia and/or unlikely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia, and methods for avoiding risks of toxicity and undesirable side effects associated with inhaled nitric oxide therapy comprising administering only non-iNO treatment modalities to these infants.
A61K 33/00 - Medicinal preparations containing inorganic active ingredients
G01N 33/84 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving inorganic compounds or pH
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A61K 9/00 - Medicinal preparations characterised by special physical form
G01N 33/497 - Physical analysis of biological material of gaseous biological material, e.g. breath
MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED (Ireland)
Inventor
Royal, Mike Allan
Breitmeyer, James Bradley
Abstract
Described herein are compositions and methods for intravenous administration of acetaminophen at a single dose level of less than about 1000 mg for the treatment or prevention of pain (e.g., postoperative pain) and/or fever.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 9/00 - Medicinal preparations characterised by special physical form
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Mosa, Tammer
Taylor, Gerard T.
Abstract
2 content less than 2 ppm. Gaseous carbon monoxide purities of 99.998% and 99.999% are achieved by removing residual air from the gaseous carbon monoxide.
B01J 19/00 - Chemical, physical or physico-chemical processes in generalTheir relevant apparatus
B01J 19/24 - Stationary reactors without moving elements inside
B01D 53/14 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Acker, Jaron M.
Kohlmann, Thomas
Abstract
Described are methods for safer nitric oxide delivery, as well as apparatuses for performing these methods. The methods may include detecting the presence or absence of a nasal cannula, and stopping the delivery of nitric oxide or providing an alert if the cannula is disconnected. The methods may also include purging the nasal cannula if it is reconnected after a disconnection or if it is replaced by a new cannula. Other methods pertain to automatic purging of the delivery conduit if the elapsed time between successive deliveries of therapeutic gas exceeds a predetermined period of time.
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Flanagan, Craig
Freed, Simon
Klaus, John
Kohlmann, Thomas
Meglasson, Martin D.
Naidu, Manesh
Shah, Parag
Abstract
The present invention generally relates to, amongst other things, systems, devices, materials, and methods that can improve the accuracy and/or precision of nitric oxide therapy by, for example, reducing the dilution of inhaled nitric oxide (NO). As described herein, NO dilution can occur because of various factors. To reduce the dilution of an intended NO dose, various exemplary nasal cannulas, pneumatic configurations, methods of manufacturing, and methods of use, etc. are disclosed.
MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED (Ireland)
Inventor
Falligant, John C.
Tolmie, Craig R.
Abstract
Systems and methods of the present invention can enable high concentration NO to be delivered into ventilator breathing circuits, via a diffusing device, without generating undesirably large amounts of NO2.
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Tolmie, Craig R.
Milsap, Jeff
Acker, Jaron M.
Abstract
Systems and methods for compensating long term sensitivity drift of catalytic type electrochemical gas sensors used in systems for delivering therapeutic nitric oxide (NO) gas to a patient by compensating for drift that may be specific to the sensors. In at least some instances, the long term sensitivity drift of catalytic type electrochemical gas sensors can be addressed using calibration schedules, which can factor in the absolute change in set dose of NO being delivered to the patient that can drive one or more baseline calibrations. The calibration schedules can reduce the amount of times the sensor goes offline. Systems and methods may factor in actions occurring at the delivery system and/or aspects of the surrounding environment, prior to performing a baseline calibration, and may postpone the calibration and/or rejected using the sensor's output for the calibration.
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Tolmie, Craig R.
Milsap, Jeff
Acker, Jaron M.
Abstract
Systems and methods for compensating long term sensitivity drift of catalytic type electrochemical gas sensors used in systems for delivering therapeutic nitric oxide (NO) gas to a patient by compensating for drift that may be specific to the sensors. The long term sensitivity drift of catalytic type electrochemical gas sensors can be addressed using calibration schedules, which can factor in the absolute change in set dose of NO being delivered to the patient that can drive one or more baseline calibrations. The calibration schedules can reduce the amount of times the sensor goes offline. Systems and methods may factor in actions occurring at the delivery system and/or aspects of the surrounding environment, prior to performing a baseline calibration, and may postpone the calibration and/or rejected using the sensor's output for the calibration.
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Tolmie, Craig R.
Milsap, Jeff
Acker, Jaron M.
Abstract
Described are systems and methods for compensating long term sensitivity drift of catalytic type electrochemical gas sensors used in systems for delivering therapeutic nitric oxide (NO) gas to a patient by compensating for drift that may be specific to the sensors atypical use in systems for delivering therapeutic nitric oxide gas to a patient. In at least some instances, the long term sensitivity drift of catalytic type electrochemical gas sensors can be addressed using calibration schedules, which can factor in the absolute change in set dose of NO being delivered to the patient that can drive one or more baseline calibrations. The calibration schedules can be used reduce the amount of times the sensor goes offline. Systems and methods described may factor in actions occurring at the delivery system and/or aspects of the surrounding environment, prior to performing a baseline calibration, and may postpone the calibration and/or rejected using the sensor's output for the calibration.
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
C07F 7/00 - Compounds containing elements of Groups 4 or 14 of the Periodic Table
A61K 9/00 - Medicinal preparations characterised by special physical form
36.
Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Tolmie, Craig R.
Milsap, Jeff
Acker, Jaron M.
Abstract
Systems and methods for compensating long term sensitivity drift of catalytic type electrochemical gas sensors used in systems for delivering therapeutic nitric oxide (NO) gas to a patient by compensating for drift that may be specific to the sensors. In at least some instances, the long term sensitivity drift of catalytic type electrochemical gas sensors can be addressed using calibration schedules, which can factor in the absolute change in set dose of NO being delivered to the patient that can drive one or more baseline calibrations. The calibration schedules can reduce the amount of times the sensor goes offline. Systems and methods may factor in actions occurring at the delivery system and/or aspects of the surrounding environment, prior to performing a baseline calibration, and may postpone the calibration and/or rejected using the sensor's output for the calibration.
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Tolmie, Craig R.
Milsap, Jeff
Acker, Jaron M.
Abstract
Described are systems and methods for compensating long term sensitivity drift of catalytic type electrochemical gas sensors used in systems for delivering therapeutic nitric oxide (NO) gas to a patient by compensating for drift that may be specific to the sensors atypical use in systems for delivering therapeutic nitric oxide gas to a patient. The long term sensitivity drift of catalytic type electrochemical gas sensors may be addressed using calibration schedules, which can factor in the absolute change in set dose of NO being delivered to the patient that can drive one or more baseline calibrations. The calibration schedules can be used to reduce the amount of times the sensor goes offline.
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Tolmie, Craig R.
Milsap, Jeff
Acker, Jaron M.
Abstract
Described are systems and methods for compensating long term sensitivity drift of catalytic type electrochemical gas sensors used in systems for delivering therapeutic nitric oxide (NO) gas to a patient by compensating for drift that may be specific to the sensors atypical use in systems for delivering therapeutic nitric oxide gas to a patient. The long term sensitivity drift of catalytic type electrochemical gas sensors may be addressed using calibration schedules, which can factor in the absolute change in set dose of NO being delivered to the patient that can drive one or more baseline calibrations. The calibration schedules can be used to reduce the amount of times the sensor goes offline.
MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED (Ireland)
Inventor
Briggs, Dennis
Do, Simon
Rabeno, Eric
Sangare, Abdoulaye
Vandlik, Mark
Fluck, Vicki
Turek, Christopher
Abstract
A photopheresis system (200) is disclosed, and that may be configured to execute one or more protocols. These protocols include: 1) protocols (400; 430; 460) for purging air out of a centrifuge bowl (210) used by the photopheresis system (200); 2) protocols (500; 510 550) for assessing the installation/operation of one or more pressure domes (330) used by the photopheresis system (200); and 3) protocols (580; 600; 660; 700; 740) for collecting buffy coat from blood processed by the photopheresis system (200).
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Tolmie, Craig R.
Milsap, Jeff
Acker, Jaron M.
Abstract
Described are systems and methods for compensating long term sensitivity drift of catalytic type electrochemical gas sensors used in systems for delivering therapeutic nitric oxide (NO) gas to a patient by compensating for drift that may be specific to the sensors atypical use in systems for delivering therapeutic nitric oxide gas to a patient. The long term sensitivity drift of catalytic type electrochemical gas sensors may be addressed using calibration schedules, which can factor in the absolute change in set dose of NO being delivered to the patient that can drive one or more baseline calibrations. The calibration schedules can be used to reduce the amount of times the sensor goes offline.
MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED (Ireland)
Inventor
Bathe, Duncan P.
Klaus, John
Christensen, David
Abstract
A nitric oxide delivery device including a valve assembly, a control module and a gas delivery mechanism is described. An exemplary gas delivery device includes a valve assembly with a valve and circuit including a memory, a processor and a transceiver in communication with the memory. The memory may include gas data such as gas identification, gas expiration and gas concentration. The transceiver on the circuit of the valve assembly may send wireless optical line-of-sight signals to communicate the gas data to a control module. Exemplary gas delivery mechanisms include a ventilator and a breathing circuit. Methods of administering gases containing nitric oxide are also described.
MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED (Ireland)
Inventor
Royal, Mike Allan
Breitmeyer, James Bradley
Abstract
Described herein are compositions and methods for intravenous administration of acetaminophen at a single dose level of less than about 1000 mg for the treatment or prevention of pain (e.g., postoperative pain) and/or fever.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 9/00 - Medicinal preparations characterised by special physical form
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Montgomery, Frederick J.
Bathe, Duncan P.
Abstract
Described are methods and systems for delivering a pharmaceutical gas to a patient. The methods and systems provide varying quantities of pharmaceutical gas delivered to the patient in two or more breaths based on the monitored respiratory rate or changes in the patient's respiratory rate.
A61M 16/20 - Valves specially adapted to medical respiratory devices
A61K 9/00 - Medicinal preparations characterised by special physical form
G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
45.
Administration and monitoring of nitric oxide in ex vivo fluids
MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED (Ireland)
Inventor
Potenziano, Jim
Hansell, Douglas R.
Griebel, Jeff
Costa, Eddie
Cooper, Lisa
Newman, David William
Abstract
Described are systems and methods for monitoring administration of nitric oxide (NO) to ex vivo fluids. Examples of such fluids include blood in extracorporeal membrane oxygenation (ECMO) circuits or perfusion fluids used for preserving ex vivo organs prior to transplanting in a recipient. The systems and methods described herein provide for administering nitric oxide to the fluid, monitoring nitric oxide or a nitric oxide marker in the fluid, and adjusting the nitric oxide administration.
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Bathe, Duncan
Klaus, John
Christensen, David
Abstract
A gas delivery system including a gas delivery device, a control module and a gas delivery mechanism is described. An exemplary gas delivery device includes a valve assembly with a valve and circuit including a memory, a processor and a transceiver in communication with the memory. The memory may include gas data such as gas identification, gas expiration and gas concentration. The transceiver on the circuit of the valve assembly may send wireless optical line-of-sight signals to communicate the gas data to a control module. Exemplary gas delivery mechanisms include a ventilator and a breathing circuit. Methods of administering gas are also described.
MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED (Ireland)
Inventor
Jamil, Khurram
Pappas, Stephen Chris
Potenziano, Jim
Abstract
The principles and embodiments of the present disclosure relate to methods for using terlipressin to treat a patient having impaired renal function associated with liver disease. A patient identified as suffering from HRS-1 is tested to determine if the patient meets at least two out of three criteria, wherein the three criteria include a WBC <4 or >12 cells/µL; HR >90 bpm; and any one of HCO3 <21 mmol/L or PaCO2 <32 mmHg or > 20 breaths per minute. If the patient meets at least two of the criteria, he or she is administered terlipressin in an amount effective to produce a reduction in serum creatinine of at least 1.0 mg/dL.
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Jamil, Khurram
Pappas, Stephen Chris
Potenziano, Jim
Abstract
2<32 mmHg or >20 breaths per minute. If the patient meets at least two of the criteria, he or she is administered terlipressin in an amount effective to produce a reduction in serum creatinine of at least 1.0 mg/dL.
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Kohlmann, Thomas
Klaus, John
Abstract
Described are systems and methods for providing a pulse of a therapeutic gas with a desired flow profile to maximize therapeutic effectiveness. Systems and methods of the present disclosure can generate and/or provide desired flow profiles with various shapes and/or properties by configuring, modifying, optimizing, and/or factoring in aspects of at least one fixed flow rate assembly of a therapeutic gas delivery system such as, but not limited to, spatial relationships of elements of the fixed flow rate assembly, rate of valve closure and opening, latent flows, transient wave generation and/or propagation, to name a few.
MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED (Ireland)
Inventor
Boucher, Christopher P.
Roe, David
Abstract
Embodiments describe methods of synthesizing metal mesoporphyrin compounds. In embodiments, a metal mesoporphyrin compound may be formed by hemin transmetallation and subsequent hydrogenation of the tin protoporphyrin IX to form a metal mesoporphyrin. In other embodiments, a method of synthesizing a metal mesoporphyrin compound comprises forming a protoporphyrin methyl ester from hemin and converting the protoporphyrin methyl ester intermediate to a metal mesoporphyrin compound through metal insertion and hydrogenation. In other embodiments, a metal mesoporphyrin compound may be formed from hemin by a hydrogen-free hydrogenation method to form a mesoporphyrin IX intermediate followed by metal insertion and hydrogenation. In embodiments, a method of synthesizing a metal mesoporphyrin compound comprises forming a mesoporphyrin IX dihydrochloride intermediate compound and converting the mesoporphyrin IX intermediate to a metal mesoporphyrin compound through metal insertion. In embodiments, a metal mesoporphyrin compound may be formed directly from hemin without isolation of any intermediates.
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
C07F 7/00 - Compounds containing elements of Groups 4 or 14 of the Periodic Table
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Acker, Jaron M.
Kohlmann, Thomas
Abstract
Described are methods for safer nitric oxide delivery, as well as apparatuses for performing these methods. The methods may include detecting the presence or absence of a nasal cannula, and stopping the delivery of nitric oxide or providing an alert if the cannula is disconnected. The methods may also include purging the nasal cannula if it is reconnected after a disconnection or if it is replaced by a new cannula. Other methods pertain to automatic purging of the delivery conduit if the elapsed time between successive deliveries of therapeutic gas exceeds a predetermined period of time.
B01D 53/04 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Acker, Jaron M.
Tolmie, Craig R.
Roehl, Robin
Schmidt, Jeffrey
Milsap, Jeff
Abstract
Therapy gas delivery systems that provide run-time-to-empty information to a user of the system and methods for administering therapeutic gas to a patient. The therapeutic gas delivery system may include a gas pressure sensor attachable to a therapeutic gas source that communicates therapeutic gas pressure data to a therapeutic gas delivery system controller, a gas temperature sensor positioned to measure gas temperature in the therapeutic gas source that communicates therapeutic gas temperature data to the therapeutic gas delivery system controller, at least one flow controller that communicates therapeutic gas flow rate data to the therapeutic gas delivery system controller, at least one flow sensor that communicates flow rate data to the therapeutic gas delivery system controller, and at least one display that communicates run-time-to-empty to a user of the therapeutic gas delivery system. The therapeutic gas delivery system controller of the system includes a processor that executes an algorithm to calculate the run-time-to-empty from the data received from the gas pressure sensor, temperature sensor, flow controller and flow sensor, and directs the result to the display.
A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
A61M 16/20 - Valves specially adapted to medical respiratory devices
A61M 16/12 - Preparation of respiratory gases or vapours by mixing different gases
A61M 16/10 - Preparation of respiratory gases or vapours
G01F 22/02 - Methods or apparatus for measuring volume of fluids or fluent solid material, not otherwise provided for involving measurement of pressure
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Acker, Jaron M.
Milsap, Jeff
Roehl, Robin
Schmidt, Jeffrey
Tolmie, Craig R.
Abstract
Therapy gas delivery systems that provide run-time-to-empty information to a user of the system and methods for administering therapeutic gas to a patient. The therapeutic gas delivery system may include a gas pressure sensor attachable to a therapeutic gas source that communicates therapeutic gas pressure data to a therapeutic gas delivery system controller, a gas temperature sensor positioned to measure gas temperature in the therapeutic gas source that communicates therapeutic gas temperature data to the therapeutic gas delivery system controller, at least one flow controller that communicates therapeutic gas flow rate data to the therapeutic gas delivery system controller, at least one flow sensor that communicates flow rate data to the therapeutic gas delivery system controller, and at least one display that communicates run-time-to-empty to a user of the therapeutic gas delivery system. The therapeutic gas delivery system controller of the system includes a processor that executes an algorithm to calculate the run-time-to-empty from the data received from the gas pressure sensor, temperature sensor, flow controller and flow sensor, and directs the result to the display.
G01F 22/02 - Methods or apparatus for measuring volume of fluids or fluent solid material, not otherwise provided for involving measurement of pressure
A61M 16/20 - Valves specially adapted to medical respiratory devices
A61M 16/12 - Preparation of respiratory gases or vapours by mixing different gases
A61M 16/10 - Preparation of respiratory gases or vapours
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Acker, Jaron M.
Falligant, John C.
Milsap, Jeff
Roehl, Robin
Schmidt, Jeffrey
Tolmie, Craig R.
Abstract
Therapy gas delivery systems that provide run-time-to-empty information to a user of the system and methods for administering therapeutic gas to a patient. The therapeutic gas delivery system may include a gas pressure sensor attachable to a therapeutic gas source that communicates therapeutic gas pressure data to a therapeutic gas delivery system controller, a gas temperature sensor positioned to measure gas temperature in the therapeutic gas source that communicates therapeutic gas temperature data to the therapeutic gas delivery system controller, at least one flow controller that communicates therapeutic gas flow rate data to the therapeutic gas delivery system controller, at least one flow sensor that communicates flow rate data to the therapeutic gas delivery system controller, and at least one display that communicates run-time-to-empty to a user of the therapeutic gas delivery system. The therapeutic gas delivery system controller of the system includes a processor that executes an algorithm to calculate the run-time-to-empty from the data received from the gas pressure sensor, temperature sensor, flow controller and flow sensor, and directs the result to the display.
G01F 22/02 - Methods or apparatus for measuring volume of fluids or fluent solid material, not otherwise provided for involving measurement of pressure
A61M 16/20 - Valves specially adapted to medical respiratory devices
A61M 16/12 - Preparation of respiratory gases or vapours by mixing different gases
A61M 16/10 - Preparation of respiratory gases or vapours
Systems and method for delivery of therapeutic gas to patients, in need thereof, receiving breathing gas from a ventilator that varies at least pressure and/or flow using enhanced therapeutic gas (NO) flow measurement
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Acker, Jaron M.
Tolmie, Craig R.
Abstract
The present disclosure generally relates to systems and methods for delivery of therapeutic gas to patients, in need thereof, receiving breathing gas from a high frequency ventilator using at least enhanced therapeutic gas (e.g., nitric oxide, NO, etc.) flow measurement. At least some of these enhanced therapeutic gas flow measurements can be used to address some surprising phenomenon that may, at times, occur when wild stream blending therapeutic gas into breathing gas a patient receives from a breathing circuit affiliated with a high frequency ventilator. Utilizing at least some of these enhanced therapeutic gas flow measurements the dose of therapeutic gas wild stream blended into breathing gas that the patient receives can at least be more accurate and/or under delivery of therapeutic gas into the breathing gas can be avoided and/or reduced.
Mallinckrodt Hospital Product IP Limited (Ireland)
Inventor
Acker, Jaron M.
Tolmie, Craig R.
Abstract
The present invention generally relates to systems and method for delivery of therapeutic gas to patients in need thereof using enhanced breathing circuit gas (BCG) flow measurement. At least some of these enhanced BCG flow measurements can be used to address some surprising phenomena that may, at times, occur when wild stream blending therapeutic gas into breathing gas that a patient receives from a breathing circuit affiliated with a ventilator. Utilizing at least some of these enhanced BCG flow measurements the dose of therapeutic gas wild stream blended into breathing gas that the patient receives from a ventilator can at least be more accurate and/or over delivery of therapeutic gas into the breathing gas can be avoided and/or reduced.
A61M 16/10 - Preparation of respiratory gases or vapours
A61M 16/01 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes specially adapted for anaesthetising
60.
Gas delivery device and system for use in magnetic resonance imaging
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Flanagan, Craig
Newman, David
Acker, Jaron M.
Tolmie, Craig R.
Potenziano, Jim
Abstract
The present invention relates to a device and method of delivering inhaled Nitric Oxide (iNO) to a patient situated in a Magnetic Resonance Imaging (MRI) suite.
A61M 16/12 - Preparation of respiratory gases or vapours by mixing different gases
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED (Ireland)
Inventor
Tolmie, Craig R.
Milsap, Jeff
Acker, Jaron M.
Abstract
Described are systems and methods for compensating long term sensitivity drift of catalytic type electrochemical gas sensors used in systems for delivering therapeutic nitric oxide (NO) gas to a patient by compensating for drift that may be specific to the sensors atypical use in systems for delivering therapeutic nitric oxide gas to LAa patient. In at least some instances, the long term sensitivity drift of catalytic type electrochemical gas sensors can be addressed using calibration schedules, which can factor in the absolute change in set dose of NO being delivered to the patient that can drive one or more baseline calibrations. The calibration schedules can be used reduce the amount of times the sensor goes offline. Systems and methods described may factor in in actions occurring at the delivery system and/or aspects of the surrounding environment, prior to performing a baseline calibration, and may postpone the calibration and/or rejected using the sensor's output for the calibration.
Therapeutic medical device for extracorporeal photopheresis in the nature of extracting blood from the body, separating blood, treating it for therapeutic purposes, and returning it to the body; medical devices for the treatment of immune system dysfunction, including rebalancing the immune system, immune system regulation and restoration
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Bathe, Duncan P.
Klaus, John
Christensen, David
Abstract
A gas delivery system including a gas delivery device, a control module and a gas delivery mechanism is described. An exemplary gas delivery device includes a valve assembly with a valve and circuit including a memory, a processor and a transceiver in communication with the memory. The memory may include gas data such as gas identification, gas expiration and gas concentration. The transceiver on the circuit of the valve assembly may send wireless optical line-of-sight signals to communicate the gas data to a control module. Exemplary gas delivery mechanisms include a ventilator and a breathing circuit. Methods of administering gas are also described.
MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED (Ireland)
Inventor
Potenziano, Jim
Hansell, Douglas R.
Griebel, Jeff
Costa, Eddie
Cooper, Lisa
Abstract
Described are systems and methods for monitoring administration of nitric oxide (NO) to ex vivo fluids. Examples of such fluids include blood in extracorporeal membrane oxygenation (ECMO) circuits or perfusion fluids used for preserving ex vivo organs prior to transplanting in a recipient. The systems and methods described herein provide for administering nitric oxide to the fluid, monitoring nitric oxide or a nitric oxide marker in the fluid, and adjusting the nitric oxide administration.
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Acker, Jaron
Tolmie, Craig R.
Abstract
The present invention provides clinical decision support that can be used with non-portable and portable systems when delivering and/or monitoring delivery of a therapeutic gas comprising nitric oxide to a patient. Further, clinical decision support can be used with non-portable and portable systems during delivery and/or monitoring of delivery of therapeutic gas when nebulized drugs may and/or may not be being delivered to a patient (e.g., when nebulizers are delivered upstream in the inspiratory limb of the breathing circuit, into a breathing gas delivery system, etc.).
A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
A61M 16/12 - Preparation of respiratory gases or vapours by mixing different gases
A61M 16/10 - Preparation of respiratory gases or vapours
G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Montgomery, Frederick J.
Bathe, Duncan P.
Abstract
th breath, where n is greater than or equal to 1. The pharmaceutical gases include CO and NO, both of which are provided as a concentration in a carrier gas. The gas control system determines the delivery of the pharmaceutical gas to the patient to result in the known desired quantity (e.g. in molecules, milligrams or other quantified units) of the pharmaceutical gas being delivered. Upon completion of that known desired quantity of pharmaceutical gas over a plurality of breaths, the system can either terminate, continue, activate and alarm, etc.
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Bathe, Duncan P.
Klaus, John
Christensen, David
Abstract
A nitric oxide delivery device including a valve assembly, a control module and a gas delivery mechanism is described. An exemplary gas delivery device includes a valve assembly with a valve and circuit including a memory, a processor and a transceiver in communication with the memory. The memory may include gas data such as gas identification, gas expiration and gas concentration. The transceiver on the circuit of the valve assembly may send wireless optical line-of-sight signals to communicate the gas data to a control module. Exemplary gas delivery mechanisms include a ventilator and a breathing circuit. Methods of administering gases containing nitric oxide are also described.
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Flanagan, Craig
Freed, Simon
Klaus, John
Kohlmann, Thomas
Meglasson, Martin D.
Naidu, Manesh
Shah, Parag
Abstract
The present invention generally relates to, amongst other things, systems, devices, materials, and methods that can improve the accuracy and/or precision of nitric oxide therapy by, for example, reducing the dilution of inhaled nitric oxide (NO). As described herein, NO dilution can occur because of various factors. To reduce the dilution of an intended NO dose, various exemplary nasal cannulas, pneumatic configurations, methods of manufacturing, and methods of use, etc. are disclosed.
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Acker, Jaron
Kohlmann, Thomas
Tolmie, Craig R.
Abstract
Described are methods and devices for therapeutic or medical gas delivery that utilize at least one proportional control valve and at least one binary control valve. The proportional control valve may be in series with the binary control valve to provide a valve combination capable of pulsing therapeutic gas at different flow rates, depending on the setting of the proportional control valve. Alternatively, the proportional control valve and binary control valve may be in parallel flow paths.
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Acker, Jaron
Kohlmann, Thomas
Tolmie, Craig R.
Abstract
Described are methods and devices for therapeutic or medical gas delivery that utilize at least one proportional control valve and at least one binary control valve. The proportional control valve may be in series with the binary control valve to provide a valve combination capable of pulsing therapeutic gas at different flow rates, depending on the setting of the proportional control valve. Alternatively, the proportional control valve and binary control valve may be in parallel flow paths.
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Potenziano, Jim
Hansell, Douglas R.
Griebel, Jeff
Costa, Eddie
Cooper, Lisa
Abstract
Described are systems and methods for monitoring administration of nitric oxide (NO) to ex vivo fluids. Examples of such fluids include blood in extracorporeal membrane oxygenation (ECMO) circuits or perfusion fluids used for preserving ex vivo organs prior to transplanting in a recipient. The systems and methods described herein provide for administering nitric oxide to the fluid, monitoring nitric oxide or a nitric oxide marker in the fluid, and adjusting the nitric oxide administration.
MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED (Ireland)
Inventor
Mosa, Tammer
Taylor, Gerard T.
Abstract
Apparatus for making at least 99.99% pure gaseous carbon monoxide comprising a reactor vessel, a cooling vessel, a compressor and optionally a chiller, a dryer or a pressurized cylinder. The chiller can be adapted to chill the scrubbed carbon monoxide gas to a temperature in the range of −30° C. to −90° C. to remove impurities. The dryer can be adapted to dry the scrubbed gaseous carbon monoxide to remove impurities. The pressurized cylinder can be adapted to store the compressed gaseous carbon monoxide.
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Flanagan, Craig
Freed, Simon
Klaus, John
Kohlmann, Thomas
Meglasson, Martin D.
Naidu, Manesh
Shah, Parag
Abstract
Described are nasal cannulas that improve the precision of the delivered dose for nitric oxide therapy by reducing the dilution of nitric oxide. The nasal cannulas may reduce the total volume and potential for retrograde flow during nitric oxide therapy through the design of the specific dimensions of the flow path and/or having check valves in the nitric oxide delivery line and/or having a flapper or umbrella valve dedicated to nitric oxide delivery. The nasal cannulas may also use materials that limit oxygen diffusion through the cannula walls. The nosepiece for these cannulas may be manufactured by a molding technique.
A01N 55/02 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur containing metal atoms
C07B 47/00 - Formation or introduction of functional groups not provided for in groups
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
75.
Apparatus and method for monitoring nitric oxide delivery
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Tolmie, Craig R.
Schnitman, Robert
Medicis, Joseph J.
Potenziano, Jim
Acker, Jaron
Schmidt, Jeffrey
Abstract
Described is an apparatus for monitoring nitric oxide delivery, wherein such apparatus comprises a display that provides a visual and/or numeric indication of the calculated dose of nitric oxide. Also described is a method of monitoring nitric oxide delivery, wherein the breathing gas flow rate and therapeutic gas flow rate are measured and used to determine the calculated dose of nitric oxide, which is then displayed. In some embodiments, an alert is provided when the calculated dose rises above or falls below a predetermined level or range.
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Montgomery, Frederick J.
Bathe, Duncan P.
Abstract
Described are methods and systems for delivering a pharmaceutical gas to a patient. The methods and systems provide varying quantities of pharmaceutical gas delivered to the patient in two or more breaths based on the monitored respiratory rate or changes in the patient's respiratory rate.
Mallinckrodt Hospital Products IP Limited (Ireland)
Inventor
Schnitman, Robert
Medicis, Joseph J.
Potenziano, Jim
Acker, Jaron
Schmidt, Jeffrey
Abstract
Described is an apparatus for monitoring nitric oxide delivery, wherein such apparatus comprises an indicator to inform a user of the apparatus when the flow of breathing gas rises above or falls below a predetermined level or range. Also described is a method of monitoring nitric oxide delivery, wherein the flow of breathing gas is measured and displayed. In some embodiments, an alert is provided when the flow of breathing gas rises above or falls below a predetermined level or range.
MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED (Ireland)
Inventor
Boucher, Christopher P.
Roe, David
Abstract
Embodiments describe methods of synthesizing metal mesoporphyrin compounds. In embodiments, a metal mesoporphyrin compound may be formed by hemin transmetallation and subsequent hydrogenation of the tin protoporphyrin IX to form a metal mesoporphyrin. In other embodiments, a method of synthesizing a metal mesoporphyrin compound comprises forming a protoporphyrin methyl ester from hemin and converting the protoporphyrin methyl ester intermediate to a metal mesoporphyrin compound through metal insertion and hydrogenation. In other embodiments, a metal mesoporphyrin compound may be formed from hemin by a hydrogen-free hydrogenation method to form a mesoporphyrin IX intermediate followed by metal insertion and hydrogenation. In embodiments, a method of synthesizing a metal mesoporphyrin compound comprises forming a mesoporphyrin IX dihydrochloride intermediate compound and converting the mesoporphyrin IX intermediate to a metal mesoporphyrin compound through metal insertion. In embodiments, a metal mesoporphyrin compound may be formed directly from hemin without isolation of any intermediates.
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
A01N 55/02 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur containing metal atoms
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
C07B 47/00 - Formation or introduction of functional groups not provided for in groups
MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED (Ireland)
Inventor
Royal, Mike Allan
Breitmeyer, James Bradley
Abstract
Described herein are compositions and methods for intravenous administration of acetaminophen at a single dose level of less than about 1000 mg for the treatment or prevention of pain (e.g., postoperative pain) and/or fever.
Therapeutic medical device for extracting blood from the body, separating blood, treating it extracorporally, and returning it to the body; used for extracorporeal photopheresis, extracorporeal photo immune therapy, extracorporeal photo chemotherapy, and cellular therapies
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
pharmaceutical preparations for use in extracorporeal photopheresis, extracorporeal photo immune therapy, extracorporeal photo chemotherapy and cellular therapies
84.
High-purity large-scale preparation of stannsoporfin
C07B 47/00 - Formation or introduction of functional groups not provided for in groups
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
A01N 55/02 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur containing metal atoms
